Plain-English translation of NCT07024784 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new investigational medicine called to see if it is safe and effective for treating gynecologic cancers—cancers that start in the ovaries, fallopian tubes, or the lining around the abdomen. You would receive this medication either on its own or combined with other cancer treatments that are already used, depending on which treatment group you're assigned to.
Gynecologic cancers, especially ovarian cancer, can come back even after standard treatments. Researchers are testing this medication to see if it can help control these cancers better and offer patients new treatment options.
You likely qualify if…
You likely don't qualify if…
You would visit a hospital or clinic regularly over approximately 3 years to receive intravenous infusions of the medication on Day 1 of each 21-day cycle. Depending on which treatment arm you're assigned to, you might receive the medication alone or combined with one of several other cancer drugs. You'll have frequent medical appointments, blood tests, and imaging scans to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States